Investment & M&A transaction comps

Healthcare Investment & M&A Transaction Comps

Explore investment and M&A transactions tagged healthcare. Compare companies, buyers, dates and available valuation multiples, with reported, estimated or rumored figures clearly labelled in each comp.

Coverage includes published FundComb transactions carrying this tag. Each comp preserves its own source notes and valuation basis.

Reviewed transactions
12
With value data
3
With revenue multiples
1
Transaction years
2017–2026

Sortable transaction comps

Healthcare transaction table

Filter transactions

Narrow the table without crowding the main view.

Clear all filters

Rows with reported value

3 / 12

Acquisition EV, USD

USD 11B

Investment EV, USD

-

Median EV / revenue

3.6x

Columns

Show columns

Select up to 12 rows across filters and pages, then share or export the set.

12 shown of 12 matching transactions. Click any transaction row for more detail.

Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately.

Select for comparison
2026-07-31 Lallemand Inc. Undisclosed - -
2026-07-27 American Industrial Partners Undisclosed - -
2026-07-06 Altaris LLC 600 - -
2026-05-27 HCA Healthcare Undisclosed - -
2025-06-27 Haleon plc Undisclosed - -
VCA Inc.
Control (100%)
2017-01-09 Mars, Incorporated 9,100 3.6x -
Vyne Medical
Control
- MRO Undisclosed - -
- GE HealthCare 945 - -
- CoreHealth Technologies Undisclosed - -
- Funds managed by Blue Owl Capital Undisclosed - -
- Knox Lane Undisclosed - -
E-Pharma Trento
Control (100%)
- Wise Equity Undisclosed - -

Source coverage varies by transaction. Announced deals, minority investments and capital raises retain their own labels; an investment amount is separate from enterprise value. Read the methodology.

Values may be estimated, rumored, incomplete or derived from public information. Transaction comps are informational and should not be relied on as financial, investment or valuation advice.